Engineered phages in anti-infection and anti-tumor fields: A review

Cao, Xiangyu; Yu, Tong; Sun, Zhe; Chen, Mengge; Xie, Wenhai; Pang, Qiuxiang; Deng, Hongkuan

doi:10.1016/j.micpath.2024.107052

Microbial Pathogenesis

2025

DOI: 10.1016/j.micpath.2024.107052

|View full text |Cite

Engineered phages in anti-infection and anti-tumor fields: A review

Xiangyu Cao,

Tong Yu,

Zhe Sun

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 92 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Current Knowledge on CRISPR Strategies Against Antimicrobial-Resistant Bacteria

de la Fuente Tagarro,

Martín-González,

De Lucas

et al. 2024

Antibiotics

View full text Add to dashboard Cite

CRISPR/Cas systems have emerged as valuable tools to approach the problem of antimicrobial resistance by either sensitizing or lysing resistant bacteria or by aiding in antibiotic development, with successful applications across diverse organisms, including bacteria and fungi. CRISPR/Cas systems can target plasmids or the bacterial chromosome of AMR-bacteria, and it is especially necessary to have an efficient entry into the target cells, which can be achieved through nanoparticles or bacteriophages. Regarding antibiotic development and production, though the use of CRISPR/Cas in this field is still modest, there is an untapped reservoir of bacterial and fungal natural products, with over 95% yet to be characterized. In Streptomyces, a key antibiotic-producing bacterial genus, CRISPR/Cas has been successfully used to activate silent biosynthetic gene clusters, leading to the discovery of new antibiotics. CRISPR/Cas is also applicable to non-model bacteria and different species of fungi, making it a versatile tool for natural products discovery. Moreover, CRISPR/Cas-based studies offer insights into metabolic regulation and biosynthetic pathways in both bacteria and fungi, highlighting its utility in understanding genetic regulation and improving industrial strains. In this work, we review ongoing innovations on ways to treat antimicrobial resistances and on antibiotic discovery using CRISPR/Cas platforms, highlighting the role of bacteria and fungi in these processes.

show abstract

Current Knowledge on CRISPR Strategies Against Antimicrobial-Resistant Bacteria

de la Fuente Tagarro,

Martín-González,

De Lucas

et al. 2024

Antibiotics

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Engineered phages in anti-infection and anti-tumor fields: A review

Cited by 1 publication

References 92 publications

Current Knowledge on CRISPR Strategies Against Antimicrobial-Resistant Bacteria

Current Knowledge on CRISPR Strategies Against Antimicrobial-Resistant Bacteria

Contact Info

Product

Resources

About